Involvement of Cytochrome P450 3A4 and P-glycoprotein in First-pass Intestinal Extraction of Omeprazole in Rabbits

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2009 Oct 13

PMID 19820718

Citations 6

Authors

Hai-Ming Fang

Jian-Ming Xu

Qiao Mei

Lei Diao

Mo-Li Chen

Juan Jin

Xin-Hua Xu

Affiliations

Soon will be listed here.

Abstract

Aim: To quantitatively evaluate in vivo first-pass intestinal extraction of omeprazole and to investigate the possible involvement of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in this process in rabbits.

Methods: Pharmacokinetic parameters were examined after intraduodenal (id), intraportal venous (ipv), and intravenous (iv) administration of omeprazole at various doses to intestinal and vascular access-ported rabbits. Extraction ratios in the liver and intestinal tract were determined from the area under the plasma concentration-time curve (AUC). In addition, omeprazole was administered by id or iv to rabbits alone or 30 min after the id administration of CYP3A4 or P-gp inhibitors (ketoconazole or verapamil, respectively).

Results: Pharmacokinetic parameters of omeprazole were dose-dependent after id, ipv, and iv administration at various doses. After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively. Compared with the control group, the presence of ketoconazole (60 mg/kg) or verapamil (9 mg/kg) significantly increased the area under the plasma concentration time curve (AUC) and the peak concentration (C(max)) of id-administered omeprazole, while it had no significant effect on omeprazole administered by iv.

Conclusion: Oral omeprazole undergoes marked extraction in the small intestine, and increased bioavailability of the drug after id administration of ketoconazole and verapamil suggests that this increase results from inhibition of CYP3A4 and P-gp function in the intestine rather than the liver.

Citing Articles

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.

Nader A, Mostafa N, Kim E, Shebley M Clin Transl Sci. 2022; 15(5):1269-1280.

PMID: 35137535 PMC: 9099122. DOI: 10.1111/cts.13247.

Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.

Sun X, Tang S, Hou B, Duan Z, Liu Z, Li Y BMC Gastroenterol. 2021; 21(1):2.

PMID: 33407159 PMC: 7789354. DOI: 10.1186/s12876-020-01532-4.

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats.

Liu W, Liu G, Liu J Pharm Biol. 2019; 57(1):449-452.

PMID: 31290355 PMC: 6691885. DOI: 10.1080/13880209.2019.1636828.

Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models.

Vatsavai L, Kilari E J Ayurveda Integr Med. 2017; 9(3):183-189.

PMID: 29103851 PMC: 6148059. DOI: 10.1016/j.jaim.2017.04.010.

Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension.

Sun X, Duan Z, Liu Z, Tang S, Li Y, He S Exp Ther Med. 2017; 12(6):3716-3722.

PMID: 28105103 PMC: 5228395. DOI: 10.3892/etm.2016.3808.

References

Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L . Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299(2):620-8. View

Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10(7):1093-5. DOI: 10.1023/a:1018943613122. View

Sutyak J, Lee Y, Perry B, Stern W, Makhey V, Sinko P . Improved longevity and functionality of a canine model providing portal vein and multi-site intestinal access. Comp Med. 2000; 50(2):167-74. View

Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi A, Eichelbaum M . Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther. 2004; 76(3):230-8. DOI: 10.1016/j.clpt.2004.04.013. View

Ward K, Stelman G, Morgan J, Zeigler K, Azzarano L, Kehler J . Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos. 2004; 32(2):172-7. DOI: 10.1124/dmd.32.2.172. View

Kunta J, Lee S, Perry B, Lee Y, Sinko P . Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metab Dispos. 2004; 32(11):1293-8. DOI: 10.1124/dmd.104.000752. View

Lee Y, Perry B, Lee H, Kunta J, Sutyak J, Sinko P . Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharm Res. 2002; 18(12):1721-8. DOI: 10.1023/a:1013374630274. View

Kaminsky L, Zhang Q . The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos. 2003; 31(12):1520-5. DOI: 10.1124/dmd.31.12.1520. View

Tam-Zaman N, Tam Y, Tawfik S, Wiltshire H . Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res. 2004; 21(3):436-42. DOI: 10.1023/B:PHAM.0000019296.47762.3f. View

10.

Hu X, Xu J, Hu Y, Mei Q, Xu X . Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharm Ther. 2007; 32(5):517-24. DOI: 10.1111/j.1365-2710.2007.00851.x. View

11.

Yamazaki M, Neway W, Ohe T, Chen I, Rowe J, Hochman J . In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001; 296(3):723-35. View

12.

Paine M, Hart H, Ludington S, Haining R, Rettie A, Zeldin D . The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006; 34(5):880-6. PMC: 2222892. DOI: 10.1124/dmd.105.008672. View

13.

Cousein E, Barthelemy C, Poullain S, Simon N, Lestavel S, Williame V . P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(4):878-86. DOI: 10.1016/j.pnpbp.2007.01.028. View

14.

Schuetz E, Umbenhauer D, Yasuda K, Brimer C, Nguyen L, Relling M . Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol. 2000; 57(1):188-97. View

15.

Blum R . Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm. 1996; 53(12):1401-15. DOI: 10.1093/ajhp/53.12.1401. View

16.

Kunta J, Sinko P . Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab. 2004; 5(1):109-24. DOI: 10.2174/1389200043489144. View

17.

Kunta J, Perry B, Sutyak J, Sinko P . Development of a novel intestinal and vascular access port (IVAP) rabbit model to study regiospecific oral absorption pharmacokinetics. Comp Med. 2002; 51(4):349-56. View

18.

Robinson M, Horn J . Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003; 63(24):2739-54. DOI: 10.2165/00003495-200363240-00004. View

19.

Hoffman D, Seifert T, Borre A, Nellans H . Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res. 1995; 12(6):889-94. DOI: 10.1023/a:1016221322886. View

20.

Chan L, Lowes S, Hirst B . The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004; 21(1):25-51. DOI: 10.1016/j.ejps.2003.07.003. View